Even the larger, blue-chip biotechnology companies are not immune to the industry’s boom-or-bust mechanics. Moderna Inc. (ticker: MRNA) is perhaps the clearest recent example. After its COVID-19 vaccine turned the company into a household name, Moderna shares surged above $400 in 2021 before …